Indolent B-Cell Non-Hodgkin Lymphoma
11 clinical trials · Condition
◉ Watch Indolent B-Cell Non-Hodgkin Lymphoma
| Record | Firm | Date |
|---|---|---|
| Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma (NCT05169658) | University of Washington | 2022-03-23 |
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (NCT05025800) | M.D. Anderson Cancer Center | 2021-10-13 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma (NCT04578600) | Joseph Tuscano | 2020-10-23 |
| A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL (NCT03571568) | BioInvent International AB | 2018-05-16 |
Track Indolent B-Cell Non-Hodgkin Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.